Introduction
The acquired immune deficiency syndrome (AI DS), caused by Human Immunodeficiency virus (HIV), is primarily a disease of the immune system characterized by severe T-cell deficiency and abnormal B-cell behaviour, clinically observable in an increased occurence of opportunistic infections and of Kaposi 's sarcoma (1 -3) . The typical laboratory features of AIDS include lymphopenia, a drastic reduction in the number of CD4 lymphocytes, reversal of the CD4 (helper/inducer) to CD8 (suppressor/cytotoxic) ratio and a depressed proliferative response to mitogens, antigens, alloantigens and autoantigens (1 -5) . Although the activation of the cellular immune system seems to contrast with the clinical features of AIDS, the high serum levels of cx,-thymosin, acid-labile interferon-cx (6), the soluble interleukin-2 receptor (r IL-2) (7) and neopterin (8) are consistent with such activation. More recently two new markers for activated cell mediated immunity have been observed to increase in AIDS : soluble CD8 (9) and interferon-y Il Author to whom correspond ence should bc a ddressed.
Pteridines Vol. 2 1990 No. 1 Copyright (" 1990 \\·a lt cr d e Gruyter . Berlin· New York (IFN-y) (10) , in serum and on lymphocytes from patients respectively. In this study we sought to determine the relevance of activated cell-mediated immunity in HIV-infected patients. as defined by four markers (neopterin, soluble r IL-2, soluble CD8, and IFN-y), comparing it with the clinical stages of HIV infection.
Materials and Methods

Subjects
Blood was taken from 67 HIV-infected patients (all I. V. drug abusers; 48 men, 19 women; age range 17 -54; mean ± SD of 29.3 ± 6.7). Infection was established by enzyme-linked immunosorbent assay (ELISA) (Wellcozyme anti-HTLV-III; Wellcome Diagnostic, Dartford, U . K.) and confirmed by Western Blot (11) . Clinical status was defined by the physician following the CDC classification system (12) . Subjects were grouped according to the stage of their disease: 24 patients were in stage IV-C and had no acute opportunistic infection at the time of investigation ; 18 were in stage III ; the remaining 25 patients were in stage II. Blood was also obtained from the following subjects: a) 67 healthy blood donors, age-and sex-matched with the 67 HIV-infected patients, b) 20 HIV-seronegative healthy 1. V. drug abusers (14 men, 6 women; age range 19 -32; mean ± SO of 23 ± 4.6) .
Serum collection and cell separation
Sera obtained to determine the presence of neopterin, soluble r IL-2, and soluble CD8 were aliquoted and stored frozen at -70 cC; after testing each aliquot was thawed and discarded. Peripheral-blood mononuclear cells (PBMC) were separated from heparinized blood by Ficoll-Hypaque density gradient (Pharmacia, Uppsala, Sweden).
IFN -y assay
An indirect immunofluorescence assay to detect IFNy on lymphocytes was recently developed, using Monoclonal antibody (MAb) IGMB-14 as a specific reagent. MAb IGMB-14 unlike previous anti-IFN-y MAbs, recognizes in Western blot two polypeptides of MW 2S,000 and 56,000 present in affinity purified IFN-y preparations, without reacting with the IFNy subspecies whose molecular weight is already known (namely MW 25 ,000 and 20,000); it is also able to recognize the new molecular weight IFN-y subspecies on the surface of circulating lymphocytes (13) . The assay was performed as earlier described (10, 13) . 
Soluble CDS assay
Soluble CDS levels in serum were determined by using a Cell Free CDS enzyme-linked immunosorbent assay, (ELISA) test kit (T cell Sciences, Inc. , Cambridge, MA). The standards and sera were added to anti-CDS MAb-coated polystyrene micro titer plate-wells. After incubation, the wells were washed to remove
Caruso et af. : T-cell activation and HIV infection unreactive sample components. An enzyme-conjugated anti-CDS MAb directed against a second epitope on the CDS molecule was then added, so that it would bind to the CDS captured by the first antibody. After removal of unbound enzyme-conjugated anti-CDS MAb by washing, substrate solution was added to the wells . The reaction was terminated by the addition of stop solution, and absorbance at 490 nm was measured with an ELISA reader. A standard curve was plotted from fi ve CDS standards: unknown values were determined from the standard curve and expressed in units per milliliter (U j ml).
Soluble r IL-2 assay
Interleukin-2 receptors in serum were assayed with a Cell free (r IL-2) ELISA test kit (T cell Sciences). The standards and sera were added to the anti-r IL-2 MAb coated polystyrene micro titer plate wells . After incubation, the wells were washed and enzyme conjugated anti r IL-2 MAb directed against a second epitope of the soluble receptor was added . After removal of unbound enzyme conjugated anti-r IL-2 MAb by washing, a substrate solution was added to the wells. The reaction was termined by adding stop-solution and absorbance was then measured at 490 nm using an ELISA reader. Unknown r IL-2 values were determined from the standard curve, which was plotted from four r IL-2 standards, and expressed in U jml.
Neopterin assay
Neopterin levels in serum were determined by Henning Berlin neopterin assay (Henning Berlin GmbH , Berlin, FRG), for which 125I-labeled neopterin and a specific anti-neopterin antiserum are used. The percentage of bound 125 I-labeled antigen decreases as a function of increasing concentrations of unlabeled antigen. The bound and free radiolabeled antigens were separated by precipitation of the antigen-antibody complexes with polyethylene glycol. The quantity of unlabeled antigen in an unknown sample was determined by comparing the radioactivity of the precipitate after centrifugation with that of known standards. The neopterin levels were expressed in nanomoles per liter (nmolj L).
Statistical analysis
Data were then analyzed by Student's t test to determine significant differences between group means.
Significance was defined as p < 0.05. The whole study was performed without any prior knowledge of the clinical status or stage of patients.
Results
IFN-yassay
The 
Soluble r IL-2 assay
The soluble r IL-2 level In the sera of 67 normal controls was 230 ± 117 U Iml, compared to 418 ± 185 U I ml in the sera of HIV -seronegative asymp- 
Neopterin assay
Neopterin values in normal controls, HIV-seronegative drug abusers, and patients in stage II, III and IV -e, are shown in Figure 4 . The mean neopterin level in the sera of normal controls was 5.5 ± 2.47 nmol /L, compared with 6.39 ± 2.41 nmol /L in the sera of HIV -seronegative I. V. drug abusers. This increase in the sera of HIV -seronegative I. V. drug abusers is not statistically significant when compared with levels in the sera of healthy subjects and of stage II patients (7.9 ± 3.08) (p > 0.05). However, neopterin levels found in sera of stage II patients are statistically significant when compared to those in the sera of healthy subjects (p < 0.05). Neopterin levels in stage III patients did not differ from those observed in stage II patients (7.81 ± 2.93) (p> 0.05). The mean neopterin level in the sera of stage IV-e patients was 29.7 ± 22.7 nmol /L: this increase is highly significant when compared to neopterin levels detected in the sera of all the other groups of tested subjects (p < 0.01). 
Discussion
For immune response to occur after antigenic challenge, an antigen should not only be recognized by specific lymphocytes, but its recognition must lead to varied cellular response. The activation of resting Tlymphocytes is the most critical process in the immune response, because cellular activation allows such cells to explete their regulatory or effector activities. This study aimed at determining the relevance of activated cell-mediated immunity in HIV-infected patients, The assay is rapid and straightforward, but also sensitive and specific. Despite the other markers which are detected in serum, IFN-y is evaluated on the surface of lymphocytes and can thus be studied together with the CD4 lymphocyte count, the widest used predictor of progression to AIDS (14) . (19, 20) . In addition, the production of IFN-y by mononuclear cells in response to antigens has been observed to decrease in vitro (16) while IFN-y concentrations have been found to increase in sera from HIV-infected patients (21) , as also shown above. This is no new phenomenon, since in several diseases in which the defective production of lymphokines by T cells in vitro is apparent, IFN-y values have been found to increase in serum when a sensitive assay is employed (22, 23) .
The observation of activated cell-mediated immunity and increased concentrations of IFN-y in HIV-infected patients in vivo, indicates that basic events in the interaction of T -lymphocytes and macro phages are brought about in such patients. Therefore in vitro data might reflect the continuous exposure of immune cells to antigenic challenge in vivo, as suggested by Fuchs et al. (21) . However, the presence of a true qualitative defect in the cellular immune system of AIDS patients, together with several defects in the lymphocyte-cytokine cascade, cannot be ruled out, as pointed out by several authors (15, 18) . The discovery of activated T -lymphocytes in subjects infected with HIV -1 is of crucial relevance. In vitro studies make it obvious that the replication of HIV depend strictly on the stimulation of infected cells (24) , and that the activation of cell-mediated immunity increases with the progressive stages of HIV-l infection. T-cell activation in vivo might contribute to a further spread of HIV -1 in infected subjects, as already suggested by Fuchs et al. (8, 21) . Thus, permanent or multiple stimulation of the cellular immune system could be the often discussed cofactor in the progression, of this syndrome. This thesis calls for further research into the cell-mediated immunity of HIV-infected patients, not only for an understanding of the immune mechanisms involved in AIDS, but also for new insights into its pathophysiology and its clinical features.
